Moderna Stock Skyrockets Over 19%, Merck Jumps On Late-Stage Cancer Vaccine Trial Win

· investors.com

Moderna stock skyrocketed and Merck jumped on strong late-stage trial results for their cancer vaccine in melanoma patients Wednesday.

Moderna and Merck reported strong late-stage trial results for their cancer vaccine in melanoma patients early Wednesday. Moderna shares skyrocketed more than 9...


More AI market news · Market heatmap · StrategyVerse · Quant Research · WOBR.AI